Jennifer A. Byrne

Camperdown, NSW, AU 
Camperdown, NSW, AU 

Overview

Jennifer Byrne practices practicing medicine in Camperdown, Australia.

Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Leukemia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Camperdown, NSW, Australia
Other Locations
Camperdown, VIC, Australia
Sydney, NSW, Australia
Westmead, NSW, Australia
Melbourne, VIC, Australia
Menzies, QLD 4222, Australia
ACT, Australia
Canberra, ACT 2601, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Terminated
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

113 Total Publications

AI-enabled exploitation of open science: a response to Zil-E-Ali on safeguarding data research integrity.
AI-enabled exploitation of open science: a response to Zil-E-Ali on safeguarding data research integrity.
Journal: Journal of clinical epidemiology
Published: March 14, 2026

Frequently Asked Questions about Jennifer A. Byrne

Is Jennifer A. Byrne a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Jennifer A. Byrne is classified as an Experienced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jennifer A. Byrne participate in research or clinical trials?

Yes. Jennifer A. Byrne has published 113 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Jennifer A. Byrne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Byrne's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile